Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 75 articles:
HTML format

Single Articles

    December 2020
  1. FRIEDENREICH CM, Cook LS, Wang Q, Kokts-Porietis RL, et al
    Prospective Cohort Study of Pre- and Postdiagnosis Physical Activity and Endometrial Cancer Survival.
    J Clin Oncol. 2020;38:4107-4117.
    PubMed     Abstract available

  2. MANNUCCI A, Furniss CS, Ukaegbu C, Horiguchi M, et al
    Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.
    J Clin Oncol. 2020;38:4086-4094.
    PubMed     Abstract available

    November 2020
  3. MILLER DS, Filiaci VL, Mannel RS, Cohn DE, et al
    Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
    J Clin Oncol. 2020;38:3841-3850.
    PubMed     Abstract available

  4. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    PubMed     Abstract available

    October 2020
  5. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    PubMed     Abstract available

  6. LAN C, Shen J, Wang Y, Li J, et al
    Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    J Clin Oncol. 2020 Oct 14:JCO2001920. doi: 10.1200/JCO.20.01920.
    PubMed     Abstract available

  7. LEON-CASTILLO A, de Boer SM, Powell ME, Mileshkin LR, et al
    Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    J Clin Oncol. 2020;38:3388-3397.
    PubMed     Abstract available

    September 2020
  8. MAKKER V, Taylor MH, Aghajanian C, Oaknin A, et al
    Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
    J Clin Oncol. 2020;38:2981-2992.
    PubMed     Abstract available

  9. GERSHENSON DM, Gourley C, Paul J
    MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
    J Clin Oncol. 2020 Sep 8:JCO2002190. doi: 10.1200/JCO.20.02190.

    August 2020
  10. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    PubMed     Abstract available

  11. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.

  12. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.

  13. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
    Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
    PubMed     Abstract available

    April 2020
  14. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available

  15. ZAMARIN D, Burger RA, Sill MW, Powell DJ Jr, et al
    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    J Clin Oncol. 2020 Apr 10:JCO1902059. doi: 10.1200/JCO.19.02059.
    PubMed     Abstract available

    March 2020
  16. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available

  17. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    PubMed     Abstract available

    February 2020
  18. PENSON RT, Valencia RV, Cibula D, Colombo N, et al
    Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    J Clin Oncol. 2020 Feb 19:JCO1902745. doi: 10.1200/JCO.19.02745.
    PubMed     Abstract available

  19. UPPAL S, Gehrig PA, Peng K, Bixel KL, et al
    Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.
    J Clin Oncol. 2020 Feb 7:JCO1903012. doi: 10.1200/JCO.19.03012.
    PubMed     Abstract available

    January 2020
  20. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
    PubMed     Abstract available

  21. TEWARI KS, Monk BJ, Burger RA
    Reply to Farolfi et al and Haines et al.
    J Clin Oncol. 2020;38:173-174.

    November 2019
  22. HAINES IE, Gabor Miklos GL
    Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.
    J Clin Oncol. 2019 Nov 7:JCO1901912. doi: 10.1200/JCO.19.01912.

  23. FAROLFI A, Lorusso D, Pignata S, De Giorgi U, et al
    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055.

    September 2019
    Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results.
    J Clin Oncol. 2019 Sep 27:JCO1902024. doi: 10.1200/JCO.19.02024.

  25. MELAMED A, Rauh-Hain JA, Ramirez PT
    Minimally Invasive Radical Hysterectomy for Cervical Cancer: When Adoption of a Novel Treatment Precedes Prospective, Randomized Evidence.
    J Clin Oncol. 2019 Sep 27:JCO1901164. doi: 10.1200/JCO.19.01164.

  26. DE JAEGHERE EA, Gremonprez FB, Tummers PG, Willaert WC, et al
    Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
    J Clin Oncol. 2019 Sep 25:JCO1901179. doi: 10.1200/JCO.19.01179.

  27. TOMAO F, Benedetti Panici P, Tomao S
    Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.
    J Clin Oncol. 2019 Sep 25:JCO1901163. doi: 10.1200/JCO.19.01163.

  28. MATULONIS UA, Walder L, Nottrup TJ, Bessette P, et al
    Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917.
    PubMed     Abstract available

    August 2019
  29. BUCKANOVICH RJ, Rustin G, Uppal S, Olawaiye AB, et al
    No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
    J Clin Oncol. 2019 Aug 26:JCO1901650. doi: 10.1200/JCO.19.01650.

  30. DA COSTA SCS, Bonadio RC, Gabrielli FCG, Aranha AS, et al
    Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
    J Clin Oncol. 2019 Aug 26:JCO1900674. doi: 10.1200/JCO.19.00674.
    PubMed     Abstract available

  31. VERGOTE I, Harter P, Chiva L
    Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?
    J Clin Oncol. 2019 Aug 12:JCO1900091. doi: 10.1200/JCO.19.00091.

  32. PUJADE-LAURAINE E, Banerjee S, Pignata S
    Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
    J Clin Oncol. 2019 Aug 12:JCO1900194. doi: 10.1200/JCO.19.00194.

  33. GERSHENSON DM, Okamoto A, Ray-Coquard I
    Management of Rare Ovarian Cancer Histologies.
    J Clin Oncol. 2019 Aug 12:JCO1802419. doi: 10.1200/JCO.18.02419.

  34. DU BOIS A, Baert T, Vergote I
    Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900022. doi: 10.1200/JCO.19.00022.

  35. ARMSTRONG DK, Walker JL
    Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900671. doi: 10.1200/JCO.19.00671.

  36. BOUBERHAN S, Pujade-Lauraine E, Cannistra SA
    Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900314. doi: 10.1200/JCO.19.00314.

  37. GOURLEY C, Bookman MA
    Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900337. doi: 10.1200/JCO.19.00337.

  38. KANDALAFT LE, Odunsi K, Coukos G
    Immunotherapy in Ovarian Cancer: Are We There Yet?
    J Clin Oncol. 2019 Aug 12:JCO1900508. doi: 10.1200/JCO.19.00508.

    June 2019
  39. KOOLE SN, van Lieshout C, van Driel WJ, van Schagen E, et al
    Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
    J Clin Oncol. 2019 Jun 28:JCO1900594. doi: 10.1200/JCO.19.00594.
    PubMed     Abstract available

  40. TEWARI KS, Burger RA, Enserro D, Norquist BM, et al
    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009.
    PubMed     Abstract available

  41. DEL CAMPO JM, Matulonis UA, Malander S, Provencher D, et al
    Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238.
    PubMed     Abstract available

    April 2019
  42. BOUBERHAN S, Shea M, Cannistra SA
    Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
    J Clin Oncol. 2019 Apr 19:JCO1900500. doi: 10.1200/JCO.19.00500.
    PubMed     Abstract available

  43. TOMAO F, Benedetti Panici P, Tomao S
    Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma.
    J Clin Oncol. 2019;37:935-936.

  44. LEHMANN V, Chemaitilly W, Lu L, Green DM, et al
    Gonadal Functioning and Perceptions of Infertility Risk Among Adult Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.
    J Clin Oncol. 2019;37:893-902.
    PubMed     Abstract available

  45. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available

  46. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    PubMed     Abstract available

  47. CHUNG HC, Ros W, Delord JP, Perets R, et al
    Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
    J Clin Oncol. 2019 Apr 3:JCO1801265. doi: 10.1200/JCO.18.01265.
    PubMed     Abstract available

    March 2019
  48. SALVADOR MU, Truelson MRF, Mason C, Souders B, et al
    Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.
    J Clin Oncol. 2019;37:647-657.
    PubMed     Abstract available

    February 2019
  49. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    PubMed     Abstract available

    January 2019
    The Boy I Never Knew.
    J Clin Oncol. 2019;37:254-255.

    August 2018
  51. SHIN DW, Lee JW, Jung JH, Han K, et al
    Disparities in Cervical Cancer Screening Among Women With Disabilities: A National Database Study in South Korea.
    J Clin Oncol. 2018 Aug 3:JCO2018777912. doi: 10.1200/JCO.2018.77.7912.
    PubMed     Abstract available

    June 2018
  52. ZOU W, Hu C, Feng Y, Wang J, et al
    Treatment Protocols for Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer.
    J Clin Oncol. 2018 Jun 13:JCO2018788893. doi: 10.1200/JCO.2018.78.8893.

  53. GUPTA VG, Goel V
    Differences Between Chemotherapy-Resistant Disease and Inoperable Disease in Cervical Cancer Treated With Neoadjuvant Chemotherapy.
    J Clin Oncol. 2018 Jun 13:JCO2018786632. doi: 10.1200/JCO.2018.78.6632.

    May 2018
  54. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
    Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
    J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
    PubMed     Abstract available

    March 2018
  55. COLOMBO N, Huang G, Scambia G, Chalas E, et al
    Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    J Clin Oncol. 2018 Mar 20:JCO2017762781. doi: 10.1200/JCO.2017.76.2781.
    PubMed     Abstract available

    February 2018
  56. GUPTA S, Maheshwari A, Parab P, Mahantshetty U, et al
    Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Feb 12:JCO2017759985. doi: 10.1200/JCO.2017.75.9985.
    PubMed     Abstract available

    January 2018
  57. CLARKE MA, Fetterman B, Cheung LC, Wentzensen N, et al
    Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
    J Clin Oncol. 2018 Jan 22:JCO2017753442. doi: 10.1200/JCO.2017.75.3442.
    PubMed     Abstract available

    November 2017
  58. FRENEL JS, Le Tourneau C, O'Neil B, Ott PA, et al
    Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
    J Clin Oncol. 2017 Nov 2:JCO2017745471. doi: 10.1200/JCO.2017.74.5471.
    PubMed     Abstract available

    October 2017
  59. BERCHUCK A, Secord AA, Moss HA, Havrilesky LJ, et al
    Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    J Clin Oncol. 2017 Oct 26:JCO2017745752. doi: 10.1200/JCO.2017.74.5752.

    August 2017
  60. PIGNATA S, Scambia G, Bologna A, Signoriello S, et al
    Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    J Clin Oncol. 2017 Aug 21:JCO2017734293. doi: 10.1200/JCO.2017.73.4293.
    PubMed     Abstract available

  61. CHILDERS CP, Childers KK, Maggard-Gibbons M, Macinko J, et al
    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
    J Clin Oncol. 2017 Aug 18:JCO2017736314. doi: 10.1200/JCO.2017.73.6314.
    PubMed     Abstract available

    May 2017
  62. BERCHUCK A, Havrilesky LJ, Kauff ND
    Is There a Role for Ovarian Cancer Screening in High-Risk Women?
    J Clin Oncol. 2017;35:1384-1386.

    April 2017
    Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
    J Clin Oncol. 2017;35:1151-1153.

  64. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    PubMed     Abstract available

    January 2017
  65. CASTLE PE, Jeronimo J, Temin S, Shastri SS, et al
    Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.
    J Clin Oncol. 2017 Jan 30:JCO2016716563. doi: 10.1200/JCO.2016.71.6563.

  66. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.

    December 2016
  67. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.

  68. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.

    September 2016
  69. MEYER LA, Cronin AM, Sun CC, Bixel K, et al
    Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
    J Clin Oncol. 2016 Sep 6. pii: JCO681239.
    PubMed     Abstract available

    August 2016
  70. DRYDEN-PETERSON S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, et al
    HIV Infection and Survival Among Women With Cervical Cancer.
    J Clin Oncol. 2016 Aug 29. pii: JCO679613.
    PubMed     Abstract available

  71. MILESHKIN LR, Freimund AE
    Improvement of Outcomes for Women With HIV Infection and Cervical Cancer.
    J Clin Oncol. 2016 Aug 29. pii: JCO690784.

    July 2016
  72. CHUANG LT, Feldman S, Nakisige C, Temin S, et al
    Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.
    J Clin Oncol. 2016 Jul 5. pii: JCO683789.

    May 2016
  73. ABDERRAHMAN B, Jordan VC
    Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity.
    J Clin Oncol. 2016 May 23. pii: JCO673137.

    March 2016
  74. KILICKAP S, Tural D
    Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?
    J Clin Oncol. 2016 Mar 21. pii: JCO653683.

    On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO663245.

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.